Skip to main content
. Author manuscript; available in PMC: 2023 Oct 1.
Published in final edited form as: Soc Psychiatry Psychiatr Epidemiol. 2022 Mar 9:10.1007/s00127-022-02249-3. doi: 10.1007/s00127-022-02249-3

Table 1.

Lifetime prevalence of DSM-IV social anxiety disorder (SAD), lifetime proportion of cases who obtained treatment and perceived treatment as helpful, and proportion of treated cases who perceived treatment as helpful

In the entire sample
Among respondents with lifetime SAD
Among respondents with lifetime SAD
Among cases that obtained lifetime SAD treatmenta
% of lifetime SAD
% of obtaining treatmenta
% of perceived treatment as helpfulb
% of perceived treatment as helpfulb
n % (SE) n % (SE) n % (SE) n % (SE)




Low and Middle Income Countries
 Colombia 4426 5.0 (0.5) 219 13.9 (3.3) 219 6.8 (2.4) 31 49.0 (12.9)
 Iraq 4332 0.8 (0.2) 35 22.7 (11.1) 35 21.1 (10.9) 6 92.8 (7.9)
 Peru 3930 2.6 (0.3) 95 18.9 (4.2) 95 7.5 (2.7) 18 39.7 (11.1)
 Shenzhen, PRC 7132 0.9 (0.2) 66 18.4 (7.1) 66 12.1 (6.0) 8 65.8 (20.4)
 Sao Paulo, Brazil 5037 5.6 (0.4) 256 21.2 (2.9) 256 13.7 (3.3) 51 64.6 (10.9)
 Bulgaria 6826 0.9 (0.2) 56 12.0 (3.5) 56 4.1 (3.1) 7 34.4 (18.6)
 Lebanon 2857 1.9 (0.4) 52 5.7 (3.5) 52 2.8 (2.7) 3 48.7 (31.5)
 Medellin, Colombia 3261 4.6 (0.5) 137 10.5 (3.0) 137 6.1 (2.4) 18 58.1 (15.0)
 Mexico 5782 2.9 (0.2) 203 13.5 (3.2) 203 9.8 (2.8) 27 72.9 (9.9)
 Romania 2357 1.3 (0.3) 29 19.5 (7.7) 29 17.1 (7.7) 5 87.6 (12.1)
High Income Countries
 Argentina 3927 2.6 (0.3) 111 31.8 (5.0) 111 18.2 (3.4) 40 57.2 (11.7)
 Australia 8463 8.5 (0.4) 740 40.7 (2.5) 740 27.3 (2.2) 302 67.0 (3.5)
 Belgium 1043 2.1 (0.5) 37 15.7 (5.6) 37 13.2 (5.0) 11 83.6 (8.4)
 France 1436 4.7 (0.7) 96 21.9 (6.2) 96 3.6 (1.6) 28 16.5 (7.3)
 Germany 1323 2.9 (0.5) 68 23.2 (5.2) 68 12.3 (3.9) 26 52.8 (10.4)
 Italy 1779 2.1 (0.3) 73 18.0 (6.3) 73 9.1 (4.0) 12 50.4 (19.9)
 Japan 4129 1.4 (0.2) 53 16.4 (6.8) 53 11.5 (4.9) 7 70.5 (22.7)
 Murcia, Spain 2621 1.7 (0.2) 43 31.7 (10.3) 43 29.8 (10.3) 15 94.1 (4.9)
 Netherlands 1094 2.4 (0.5) 59 32.5 (6.5) 59 24.1 (6.7) 19 74.0 (7.8)
 New Zealand 12790 9.5 (0.3) 1283 22.8 (1.5) 1283 15.5 (1.1) 278 67.9 (3.4)
 Northern Ireland 4340 6.0 (0.4) 283 32.5 (3.2) 283 21.7 (2.6) 88 66.7 (6.0)
 Poland 10081 1.4 (0.1) 144 19.4 (2.8) 144 14.0 (2.4) 28 72.3 (7.2)
 Portugal 3849 4.7 (0.5) 188 22.6 (3.2) 188 13.4 (2.5) 42 59.1 (8.2)
 Spain 2121 1.3 (0.3) 53 31.5 (5.9) 53 23.0 (5.5) 17 73.0 (8.6)
 US 9282 12.1 (0.4) 1143 18.0 (1.1) 1143 12.3 (1.1) 212 68.2 (3.0)
 Saudi Arabia 3638 5.5 (0.6) 164 11.6 (3.5) 164 4.0 (1.5) 23 34.1 (13.0)
All Low and Middle Income Countries 45940 2.5 (0.1) 1148 15.8 (1.3) 1148 9.5 (1.2) 174 60.4 (5.1)
All High Income Countries 71916 5.9 (0.1) 4538 24.8 (0.8) 4538 16.3 (0.6) 1148 65.9 (1.7)
All Countries 117856 4.6 (0.1) 5686 22.8 (0.7) 5686 14.9 (0.6) 1322 65.1 (1.6)
χ2 Test on DF χ2 P-value DF χ2   P-value DF χ2   P-value DF χ2   P-value




Low and Middle Income Countries 9 244.5 <.0001* 9 12.7 0.175 9 11.6 0.235 9 12.5 0.188
High Income Countries 15 1400.9 <.0001* 15 108.6 <.0001* 15 90.8 <.0001* 15 38.8 0.001*
All Countries 25 1956.2 <.0001* 25 144.2 <.0001* 25 119.9 <.0001* 25 53.5 0.001*
Low and Middle vs. High 1 398.0 <.0001* 1 26.9 <.0001* 1 17.4 <.0001* 1 1.1 0.298

Abbreviations: SE, standard error; PRC, People’s Republic of China

a

Cases are based on three conditions: (i) Respondents obtained SAD treatment; (ii) Year of first SAD treatment was 1990 or later; and (iii) Age at onset was the year of first SAD treatment or earlier.

b

Cases are based on four conditions: (i) Respondents obtained SAD treatment; (ii) Year of first SAD treatment was 1990 or later; (iii) Age at onset was the year of first SAD treatment or earlier; and (iv) Respondents obtained helpful treatment.